IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies
Received 3 January 2008; accepted 6 March 2008.
Abstract
We currently calculate area under the busulfan concentration time curve (AUC) using 7 plasma busulfan concentrations (AUC7) drawn after the first of 16 i.v. busulfan doses given as a 2-hour infusion every 6 hours. The aim of this study was to develop and validate limited sampling strategies (LSSs) using 3 or fewer busulfan concentration values with which to reliably calculate AUC in children undergoing hematopoietic stem cell transplant (HSCT). Children in the development group (44) received i.v. busulfan at Sick Kids; the validation group consisted of 35 children who received care at CHU Ste-Justine. Busulfan doses given and subsequent plasma busulfan concentrations were recorded. LSSs using 1 to 3 concentration-time points were developed using multiple linear regression. LSS were considered to be acceptable when adjusted r2 > 0.9, mean bias <15% and precision <15%. Extent of agreement between the AUC7 values and the LSS AUC was assessed by the intraclass correlation coefficient (ICC) and Bland-Altman (BA) analysis. Agreement was considered to be excellent when the lower limit of the 95% confidence limit of the ICC exceeded 0.9 and when the limits of agreement in the BA analysis were ±15% for both AUC and dose. Administration of the theoretic adjusted busulfan doses based on each LSS was simulated and cases where the resulting AUC was >1500 or <900 μM·min were noted. LSSs using 1, 2, or 3 plasma busulfan concentrations were developed that showed excellent agreement with AUC7 and adjusted busulfan doses. In the validation sample, only the 2- and 3-point LSSs demonstrated acceptable precision and lack of bias. LSSs using 2 or 3 plasma busulfan concentrations can be used to reliably estimate busulfan AUC after IV administration in children undergoing HSCT.
1Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
2Department of Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada
3Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
4Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
5Division of Haematology/Oncology, CHU Ste-Justine, Montréal, Québec, Canada
6Department of Clinical Biochemistry, CHU Ste-Justine, Montréal, Québec, Canada
7Department of Pediatrics, Université de Montréal, Montréal, Québec, Canada
8Department of Pharmacology, Université de Montréal, Montréal, Québec, Canada
9Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada
Correspondence and reprint requests: L.L. Dupuis, RPh., MScPhm., FCSHP, Department of Pharmacy, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.